Published On: 11/20/2018
TARGET PharmaSolutions to Advance Research in NASH and Hepatitis B Through New Collaboration with Gilead Sciences
CHAPEL HILL, NC – November 20, 2018 /PR NEWSWIRE/ – TARGET PharmaSolutions, Inc., a company focused on real world evidence, is pleased to announce that it has entered into a strategic partnership with Gilead Sciences for TARGET-NASH and TARGET-HBV. Gilead is the sixth partner in TARGET-NASH, joining Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Intercept and Novartis, and the first partner to join TARGET-Hepatitis B.
TARGET-NASH is a robust, meticulously-documented, longitudinal observational study that evaluates adult and pediatric patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). TARGET-NASH has enrolled over 4,250 patients to date and will enroll up to 15,000 patients in total over the coming years. TARGET-NASH is led by an academic steering committee chaired by Drs. Arun Sanyal, MD (Virginia Commonwealth University); Ken Cusi, MD (University of Florida), and Brent Tetri (Saint Louis University).
The academic steering committee co-chair, Dr. Arun Sanyal, MD stated “TARGET-NASH is critical for the scientific and regulatory community as we prepare for the plethora of new agents for the treatment of NASH. In the immediate term, it will give us a critical understanding of NASH diagnosis and management in the real world across multiple populations. In the longer term, it is the perfect platform to have a deep understanding of the safety and effectiveness of these new agents across populations not included or underrepresented in Phase 3 clinical trials.”
TARGET-HBV is an observational study that is evaluating patients with Hepatitis B. TARGET-HBV recently started enrolling patients and plans to enroll up to 5,000 patients across a diverse network of sites to advance our understanding of Hepatitis B.
Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions, stated “We are very excited to have Gilead join TARGET-NASH and TARGET-HBV. It is a privilege to partner with a company so focused on advancing the understanding of Liver Diseases.”
About Target RWE
Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.
Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit www.targetrwe.com.
Contact:
Kayla Slake
Marketing Manager
984.234.0268 ext 205
More News
-
10/11/2021
Target RWE Inflammatory Bowel Disease Research Presented at UEG Week 2021 -
09/13/2021
Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year’s Meeting -
07/01/2021
Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences -
06/29/2021
Liver International Publishes Hepatocellular Carcinoma RWE Review -
06/22/2021
Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients